Myungmoon Pharm starts to sell ‘Creon’ under co-promotion agreement with Abott Korea

Myungmoon Pharm will sell ‘Creon,’ a Abott Korea’s pancreatic enzyme replacement therapy(PERT).

Myungmoon Pharm(CEO Seok-Min Woo, Chun-Shik Park) and Aboot Korea(CEO Seung-Yoon Lee) recently signed a co-promotion agreement of ‘Creon,’ a PERT that is effective on pancreatic exocrine disorder.

Under the agreement, the two companies will jointly perform sales and marketing activities for the pro...